One door closes.

Another opens, so don’t give up on cetuximab just yet. A phase 1/2 trial of dual EGFR-blockade with panitumumab + cetuximab for recurrent or metastatic head and neck cancer demonstrates safety and activity, particularly among those who are cetuximab-naive—which, hey, may become more common. | Adkins, Lancet Oncol 2018